hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06283888, orgStudyIdInfo id: PRECISE-PCI, briefTitle: CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-04-01, completionDateStruct date: 2028-12-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Zunyi Medical College, class: OTHER, descriptionModule briefSummary: In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard DAPT. Although better understood "East Asian Paradox", finding the right CYP2C19 genotype-guided P2Y12 inhibitor selection to balance maintaining ischaemic prevention and less bleeding remains a topic in real-world clinical practice., conditionsModule conditions: ACS - Acute Coronary Syndrome, conditions: CYP2C19 Polymorphism, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: CYP2C19 Genotype Guided DAPT, interventions name: Conventional DAPT, outcomesModule primaryOutcomes measure: NACE (net adverse clinical event), secondaryOutcomes measure: Incidence of clinically significant bleeding, secondaryOutcomes measure: Incidence of MACCE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Affiliated Hospital of Zunyi Medical University, status: RECRUITING, city: Zunyi, state: Guizhou, zip: 563003, country: China, contacts name: Cai De Jin, MD, role: CONTACT, phone: 86+173-8576-9997, email: jincaide@zmu.edu.cn, contacts name: Yan Yan Jin, MD, PhD, role: CONTACT, phone: 86+157-7229-0925, email: jinyanyan850925@163.com, contacts name: Cai De Jin, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Ran Zun Zhao, MD, role: SUB_INVESTIGATOR, geoPoint lat: 27.68667, lon: 106.90722, hasResults: False
protocolSection identificationModule nctId: NCT06283875, orgStudyIdInfo id: PROMISEPLUS-301, briefTitle: The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-01-30, completionDateStruct date: 2029-01-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Geneplus-Beijing Co. Ltd., class: INDUSTRY, descriptionModule briefSummary: This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA) confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are expected to receive surgical resection or curative radiotherapy and chemotherapy. Collect baseline tumor tissue samples from patients during the treatment period, as well as peripheral blood samples (20 ml/time) from multiple treatment timepoints. Mutations in tumor tissue were detected by the 1021 genes panel, then personalized MRD monitoring probes were customized for patients, allowing for multi node peripheral blood sample ctDNA detection of enrolled patients. The clinical significance of ctDNA in prognostic stratification, recurrence monitoring, and efficacy prediction in surgical/non-surgical cervical cancer patients was explored. And compare the consistency and differences between ctDNA detection technology, imaging, and blood tumor markers in monitoring tumor disease progression, and evaluate the correlation between ctDNA status after curative treatment and patient PFS and RFS., conditionsModule conditions: Ovarian Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: DFS of enrolled patients for 2 years, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Soochow University, city: Suzhou, state: Jiangsu, zip: 215006, country: China, contacts name: Jinhua Zhou, role: CONTACT, phone: +86 13914024750, email: jsjhzh@126.com, contacts name: Songbing Qin, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06283862, orgStudyIdInfo id: HUM00231159b, secondaryIdInfos id: VMR2022-03, type: OTHER_GRANT, domain: Michigan, State of, Licensing and Regulatory Affairs, Department of 573000, briefTitle: MIVetsCan: Can-Coach Trial (Phase 2), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2027-02, completionDateStruct date: 2027-02, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: University of Michigan, class: OTHER, collaborators name: Michigan, State of, Licensing and Regulatory Affairs, descriptionModule briefSummary: The goal of the MIVetsCan Can-Coach Trial is to test four coaching sessions to help Veterans with chronic pain use their own cannabis products more effectively to manage pain and related symptoms., conditionsModule conditions: Chronic Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be randomized to immediately receive 4 sessions of tailored guidance or to receive it after 12 weeks, as a waitlist control condition., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 468, type: ESTIMATED, armsInterventionsModule interventions name: Educational Session, outcomesModule primaryOutcomes measure: Patient Global Impression of Change (PGIC) score, secondaryOutcomes measure: Self-report of pain (intensity or severity) from a numerical rating scale of 0-10, secondaryOutcomes measure: Anxiety as measured by the score on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile version 2.1, secondaryOutcomes measure: Pain interference trends as measured by the score on the PROMIS-29 Profile version 2.1, secondaryOutcomes measure: Sleep disturbance as measured by the score on the PROMIS-29 Profile version 2.1, secondaryOutcomes measure: Suicidal ideation as measured by the Positive and Negative Suicide Ideation (PANSI) - Positive ideation, secondaryOutcomes measure: Suicidal ideation as measured by the Positive and Negative Suicide Ideation (PANSI) - Negative ideation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Michigan, city: Ann Arbor, state: Michigan, zip: 48105, country: United States, contacts name: Vivian Kurtz, role: CONTACT, phone: 734-998-7156, email: vkurtz@med.umich.edu, contacts name: Kevin Boehnke, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.27756, lon: -83.74088, hasResults: False
protocolSection identificationModule nctId: NCT06283836, orgStudyIdInfo id: Dexrem ATI 4-6, briefTitle: Dexmedetomidine vs. Remifentanil Conscious Sedation for Stapedotomy/Stapedectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Iuliu Hatieganu University of Medicine and Pharmacy, class: OTHER, descriptionModule briefSummary: Dexmedetomidine continuous intravenous infusion vs. remifentanil target-controlled infusion conscious sedation for stapedotomy/stapedectomy- a prospective, single-center, double-masked randomized trialThe goal of this clinical trial is to compare monitored anesthesia care with continuous intravenous dexmedetomidine vs. remifentanil target-controlled infusion in patients undergoing stapedotomy or stapedectomy for otosclerosis. The aims of this research are:* to assess the patient's satisfaction with each sedation regimen* the surgeon will also grade their satisfaction regarding the surgical field The investigators will monitor and analyze the vitals during and after the intervention and document any intra- and postoperative complications.Participants will be randomly assigned to receive either dexmedetomidine or remifentanil, and the patient, the surgeon, and the investigator will not be aware of the treatment administered., conditionsModule conditions: Otosclerosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Dexmedetomidine, interventions name: Remifentanil, outcomesModule primaryOutcomes measure: Patient satisfaction, primaryOutcomes measure: Surgeon satisfaction, secondaryOutcomes measure: mean arterial pressure, secondaryOutcomes measure: Heart Rate, otherOutcomes measure: the need for adjuncts during intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cluj County Clinical Emergency Hospital, city: Cluj Napoca, state: Cluj, zip: 400006, country: Romania, contacts name: Caius Mihai Breazu, MD, PhD, role: CONTACT, phone: +40743010012, email: csbreazu@yahoo.com, contacts name: ioan florin marchis, MD, PhD, role: CONTACT, phone: +40757065205, email: mosku17@yahoo.com, geoPoint lat: 46.76667, lon: 23.6, hasResults: False
protocolSection identificationModule nctId: NCT06283823, orgStudyIdInfo id: 41821, briefTitle: Morphological Changes of Removable Orthodontic Retainers During the Use, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-12-21, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-12-21, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University of L'Aquila, class: OTHER, descriptionModule briefSummary: The retention is one of the stages of orthodontic treatment that aims to keep the teeth in the correct positions after orthodontic treatment. Without a retention phase, there is a tendency for the teeth to return to their initial position (relapse). To prevent relapse, at the end of orthodontic therapy the use of retaining devices to keep the teeth in their ideal position is required. The aim of the study is to analyse whether intraoral aging of removable retention devices can lead to morphological or dimensional changes, and whether or not these changes are related to orthodontic relapse, expressed as a change in the Peer Assessment Rating (PAR) index. The PAR index is an index that allows us to evaluate the relapse after orthodontic treatment. In this study the PAR index will be measured at the start of the retention period (T0), at the three-months follow-up (T1) and at the six months follow-up (T2). In particular, two types of thermoformed retainers with different cutouts will be evaluated to determine whether the presence of higher margins in a type of retainers allows to maintain greater stability over time and, therefore, to confer a mechanical and clinical advantage., conditionsModule conditions: Orthodontic Retainer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Thermoformed orthodontic retainer, outcomesModule primaryOutcomes measure: Peer Assessment Rating (PAR) index, primaryOutcomes measure: Volumetric superimposition of digital models, secondaryOutcomes measure: Thickness, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of L'Aquila, status: RECRUITING, city: L'Aquila, zip: 67100, country: Italy, contacts name: Michele Tepedino, DDS, role: CONTACT, phone: +39 340 276 1456, email: michele.tepedino@univaq.it, geoPoint lat: 42.35055, lon: 13.39954, hasResults: False
protocolSection identificationModule nctId: NCT06283810, orgStudyIdInfo id: 2023/168, briefTitle: The Effects of Interpersonal Relationship Psychotherapy and Laughter Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Istanbul University - Cerrahpasa (IUC), class: OTHER, descriptionModule briefSummary: Midwives, who have an important place in the health system, are expected to be equipped to meet the health care needs of women (Fışkın \& Doğan, 2020). Therefore, midwifery students, who are known to play a role in promoting women's health, should have good interpersonal relationships, good problem-solving skills, and high self-reflection and insight, which are assumed to be effective in both, in order to fulfill these responsibilities.Translated with DeepL.com (free version), conditionsModule conditions: Midwifery Students, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: psychotherapy of interpersonal relationships, interventions name: laughter therapy, interventions name: Plasebo, outcomesModule primaryOutcomes measure: self-reflection skills, primaryOutcomes measure: problem solving skills, primaryOutcomes measure: interpersonal relationship skills, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Istanbul University-Cerrahpasa, status: RECRUITING, city: Istanbul, zip: 34320, country: Turkey, contacts name: Betül Uncu, role: CONTACT, phone: +095078421227, email: betul.uncu@iuc.edu.tr, contacts name: Nurten Kaya, role: SUB_INVESTIGATOR, contacts name: Betül Uncu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06283745, orgStudyIdInfo id: 73225, briefTitle: Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-23, primaryCompletionDateStruct date: 2027-03-22, completionDateStruct date: 2027-03-22, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. The investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-SARS-CoV-2 olfactory loss which demonstrated safety and efficacy. Therefore, the investigators aim to assess the ability of PRP to improve olfactory function in patients with parosmia., conditionsModule conditions: Paraosmia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: PRP injections will be given to one arm while sham saline injections will be given to the other arm., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Platelet-rich Plasma (PRP), interventions name: Saline, outcomesModule primaryOutcomes measure: Change in Sniffin Sticks Parosmia Test (SSParoT), primaryOutcomes measure: Change in questionnaire of olfactory disorders (QOD) scale score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stanford Sinus Center / Stanford University School of Medicine, city: Palo Alto, state: California, zip: 94304, country: United States, contacts name: Homer Abaya, BS, role: CONTACT, phone: 650-725-6500, email: habaya@stanford.edu, contacts name: Maxime Fieux, MD, PhD, role: CONTACT, phone: +33621611643, email: fieuxma@stanford.edu, contacts name: Zara Patel, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False
protocolSection identificationModule nctId: NCT06283732, orgStudyIdInfo id: 20392, briefTitle: A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience., statusModule overallStatus: COMPLETED, startDateStruct date: 2023-11-15, primaryCompletionDateStruct date: 2024-02-15, completionDateStruct date: 2024-02-15, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Amway Corp, class: INDUSTRY, collaborators name: Citruslabs, descriptionModule briefSummary: The study aims to evaluate the effectiveness of a dietary supplement (greens powder), on improving digestive health, quality of life, energy levels, and satiety over a 14-day period. Participants, aged 18-65 and experiencing mild digestive issues, will consume the greens powder daily and report outcomes through diaries and questionnaires., conditionsModule conditions: Digestive System Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: Greens powder, outcomesModule primaryOutcomes measure: Digestive Health Improvement, secondaryOutcomes measure: Quality of Life and Well-being Enhancement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Citruslabs, city: Santa Monica, state: California, zip: 90404, country: United States, geoPoint lat: 34.01945, lon: -118.49119, hasResults: False
protocolSection identificationModule nctId: NCT06283719, orgStudyIdInfo id: ZG006-002, briefTitle: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Suzhou Zelgen Biopharmaceuticals Co.,Ltd, class: INDUSTRY, descriptionModule briefSummary: This is a multicenter, open-label phase I/II study, divided into 2 parts:Part 1 involves a dose-escalation study of ZG006 in which the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. Upon completion of Part 1, investigators and the sponsor will discuss and determine two recommended phase II doses (RP2D) based on safety, preliminary efficacy, and pharmacokinetic (PK) results for use in Part 2.Part 2 is a phase II dose-expansion study of ZG006, aiming to investigate the efficacy and safety of ZG006 in patients with advanced small cell lung cancer., conditionsModule conditions: Small Cell Lung Cancer, conditions: Neuroendocrine Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 105, type: ESTIMATED, armsInterventionsModule interventions name: ZG006, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Number of participants with adverse events (AEs), secondaryOutcomes measure: Number of participants with serious adverse events (SAEs), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Disease control rate (DCR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Chest Hospital, city: Shanghai, state: Shanghai, country: China, contacts name: Shun Lu, role: CONTACT, contacts name: Shun Lu, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06283706, orgStudyIdInfo id: 1000081113, briefTitle: The Tryptophan Requirement in Healthy Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: The Hospital for Sick Children, class: OTHER, collaborators name: Canadian Institutes of Health Research (CIHR), descriptionModule briefSummary: The aging population is growing rapidly. For the first time ever, Canadian seniors outnumbered young adults in 2016. Aging is associated with many physical and metabolic deteriorations including the loss of muscle mass and strength, insulin resistance, increased inflammation and oxidative stress.The muscles of our bodies are composed of proteins and proteins are made of small building blocks called amino acids. Our bodies have the ability to make some amino acids which are called the non-essential amino acids. However, there are certain amino acids that our body's need to make protein but can only be supplied from the foods that we consume. These are called essential amino acids. Tryptophan is one of the essential amino acids that the body needs. Tryptophan is required for protein synthesis and acts as a precursor for serotonin and nicotinic acid. Therefore, there may be a need for more threonine in the diet of older adults. However, the current requirement for threonine is based on studies conducted exclusively in young adults. Thus, the purpose of this study is to find out how much tryptophan older adults need., conditionsModule conditions: Healthy Aging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Tryptophan, outcomesModule primaryOutcomes measure: Determination of tryptophan requirement in adults >60 years of age., eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False